Alzheimer’s drugs targeting amlyoid plaque may be doomed to fail
▻https://massivesci.com/notes/aducanumab-alzheimers-fda-soluble-amyloid
In a study of the controversial drug aducanumab, cognitive decline tracked something other than high levels of amyloid plaques
